Yuhan Corporation
http://eng.yuhan.co.kr/Main/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yuhan Corporation
Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Finance Watch: Recent Upswing Turns Down, But Two Small IPOs Launch
Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital.
Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.
What Korean Biopharma Firms Need To Consider Before Deal Negotiations
A report by Korea Bio-Economy Research Center outlines key factors that could help ensure successful licensing deal negotiations for Korean biopharmas.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Yuhan USA